drugset / Trial / NCT04262141
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
Phase 2
Active not recruiting
4 enrolled
Terrence J Bradley, MD
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the hematologic effects of IMG-7289 therapy in ET and PV patients who require platelet, White Blood Cell (WBC) or Red Blood Cell (RBC) control, and have failed at least one standard therapy.
Timeline
- Start
- 2020-10-02
- Primary completion
- 2026-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bomedemstat | Small molecule | 0.6 mg/kg | Oral |